Skip to main content
Have a personal or library account? Click to login
Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation Cover

Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation

Open Access
|May 2025

Abstract

The only curative therapy for end-stage heart failure is orthotopic allogeneic heart transplantation. This therapy has extended the survival of patients worldwide but is limited due to the scarcity of donor organs. Potential alternative donor sources of organs for transplantation include genetically-modified (GM) large animal donors (ie, xenografts) and human organs developed in large animal hosts. These strategies utilize gene editing and somatic cell nuclear transfer technologies to engineer partially or completely humanized organs. Preclinical xenotransplantation studies of GM pig hearts into baboons have already provided an important clinical foundation, as two patients have received cardiac xenografts from GM pigs and have survived for up to 2 months. Additional issues need to be addressed in order for patients to survive more than 1 year, which would make these strategies clinically applicable. Thus, in combination with immunosuppression agents, xenogeneic and exogenic organ sources hold tremendous promise for an unlimited and transformative supply of organs for transplantation.

DOI: https://doi.org/10.14797/mdcvj.1590 | Journal eISSN: 1947-6108
Language: English
Page range: 92 - 99
Submitted on: Mar 4, 2025
Accepted on: Apr 7, 2025
Published on: May 15, 2025
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2025 Daniel J. Garry, Mary G. Garry, Hiromitsu Nakauchi, Hideki Masaki, David H. Sachs, Joshua I. Weiner, Daniel Reichart, Eckhard Wolf, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.